Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 115Cholangiocarcinoma 24Carcinoma, Renal Cell 20Liver Neoplasms 12Stomach Neoplasms 10Biliary Tract Neoplasms 10Thyroid Neoplasms 8Endometrial Neoplasms 8Breast Neoplasms 8Neoplasms 7Recurrence 6Neuroendocrine Tumors 5Neoplasm Metastasis 5Melanoma 5Uterine Cervical Neoplasms 4Thyroid Carcinoma, Anaplastic 4Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma, Adenoid Cystic 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Adenocarcinoma 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2

Interventions

Ipilimumab 6tremelimumab 5durvalumab 5Nivolumab 3Capecitabine 3Radiotherapy 2Radiation 2Paclitaxel 2CTLA-4 Antigen 2Blood Specimen Collection 2relatlimab 1poly ICLC 1lenvatinib 1folfirinox 1balstilimab 1Vaccines 1Vaccination 1Surgical Procedures, Operative 1Radiosurgery 1Platinum 1Peptides 1Pemetrexed 1Oxaliplatin 1Opdualag 1Monophenol Monooxygenase 1Melphalan 1Leucovorin 1Immunotherapy 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diabetes Mellitus, Insulin-Dependent, 12 × lenvatinib × Clear all
NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
48 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡